ANTX - NASDAQ
AN2 Therapeutics, Inc.
$4.07
+1.2%AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
At a Glance
Live Snapshotantx
Total Non-Current Liabilities
Last Annual Value
170.00K
3-Year CAGR
340%
5-Year CAGR
48%
10-Year CAGR
-14%
AN2 Therapeutics, Inc. Competitors Analysis of Total Non-Current Liabilities
| Company | Total Non-Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
AN2 Therapeutics, Inc. NASDAQ:ANTX | 170.00K | N/A | 67.2% | N/A | |
 Intensity Therapeutics, Inc. NASDAQ:INTS | 110.00K | -14.2% | -59.6% | N/A | |
 Verrica Pharmaceuticals Inc. NASDAQ:VRCA | 5.95M | -49.0% | 32.4% | 7.9% | |
 Q32 Bio Inc. NASDAQ:QTTB | 8.42M | -66.1% | -19.5% | 37.8% |
AN2 Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your ANTX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.